急性期の興奮と攻撃性の治療の世界市場

急性期の興奮と攻撃性の治療の世界市場は2030年までに60億米ドルに達する見込み

2024年に51億米ドルと推定される急性期の興奮と攻撃性の治療の世界市場は、分析期間2024-2030年にCAGR 2.8%で成長し、2030年には60億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである第一世代抗精神病薬は、CAGR 2.2%を記録し、分析期間終了時には29億米ドルに達すると予測されます。第二世代抗精神病薬セグメントの成長率は、分析期間中CAGR 4.3%と推定されます。

米国市場は14億米ドルと推定、中国はCAGR 5.2％で成長予測

米国の急性期の興奮と攻撃性の治療市場は2024年に14億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに12億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.1%と2.1%と予測されています。欧州では、ドイツがCAGR 1.5%で成長すると予測されています。

世界の急性期の興奮と攻撃性の治療市場- 主要動向と促進要因まとめ

なぜ急性期の興奮と攻撃性の臨床管理がヘルスケアシステム全体で優先されるようになったのか？

急性の激越と攻撃性は、精神疾患、神経障害、薬物乱用、重度の代謝障害を持つ患者にしばしば観察される重大な行動上の緊急事態です。これらのエピソードは、突然の制御不能な感情的または身体的爆発を特徴とし、暴力や自傷行為にエスカレートすることがあるため、早急な医療介入が必要となります。統合失調症、双極性障害、認知症、自閉スペクトラム症（ASD）、外傷性脳損傷などの有病率の増加により、興奮と攻撃性の効果的な治療は救急治療室、精神科病棟、長期療養施設、矯正医療環境において緊急の課題となっています。

安全かつ迅速で、患者中心の介入戦略の必要性は、拘束具の使用やスタッフの負傷に関連する法的、倫理的、業務上の潜在的リスクによってさらに高まっています。メンタルヘルスや行動上の緊急事態に対する認識が世界的に高まるにつれ、ヘルスケアプロバイダーは、鎮静や認知機能障害を最小限に抑えながら迅速に症状をコントロールできる薬理学的治療を採用することで、身体的拘束や隔離への依存を減らす必要に迫られています。このシフトは、患者の尊厳や安全性を損なうことなくデスケーリングを可能にする、即効性のある筋肉内（IM）、静脈内（IV）、舌下、吸入可能な薬物製剤に対する需要を促進しています。

製剤や投与方法の進歩は、治療効果をどのように高めているのでしょうか？

医薬品の技術革新は、急性期の激越と攻撃性の治療において変革的な役割を果たしています。主な動向は、発症時間を短縮し、患者のコンプライアンスを向上させ、侵襲的な拘束の必要性を最小限にする標的送達システムを備えた速効型抗精神病薬やベンゾジアゼピン系薬剤の開発です。オランザピン、アリピプラゾール、ジプラシドンなどの第2世代抗精神病薬（SGA）は、IM注射で投与されるが、ハロペリドールのような第1世代抗精神病薬と比較して、有効性と安全性の比率が良好で、錐体外路系副作用の発生率が低いため、人気が高まっています。

ロキサピンの吸入やデクスメデトミジンの舌下投与などの新しいデリバリーシステムは、数分以内に作用する非侵襲的で患者に好まれる代替手段を提供することで、治療の選択肢をさらに広げています。これらのルートは、非協力的な患者の服薬受け入れを改善し、臨床スタッフの物流負担を軽減します。さらに、抗精神病作用と抗不安作用を併せ持つ新規の製剤は、特定の患者集団に合わせた治療に有望です。また、認知症の高齢者や急性期医療に従事する患者において特に重要な鎮静作用や認知機能の鈍化を最小限に抑えるために、受容体選択性を有する薬剤の臨床試験が進行中です。

市場成長の原動力となっているヘルスケア動向、臨床課題、政策イニシアチブは？

精神科救急や行動障害の併発率の上昇により、病院や精神科施設は治療プロトコルを更新し、救急対応の薬理学的ソリューションをストックするよう求められています。救急部門は現在、急性薬物離脱症、神経変性疾患、知的障害、外傷による興奮状態など、より幅広い患者層を治療しており、柔軟で即効性のある薬物レジメンに対する需要を牽引しています。さらに、世界の精神科病床の不足と病院の混雑の増加に伴い、攻撃性の迅速な薬理学的コントロールは、患者の処理能力、安全性、ケアの質を向上させるために不可欠となっています。

政策面では、ヘルスケア認定機関やメンタルヘルス監督機関が、過剰な鎮静や身体拘束を推奨しない、より厳格なガイドラインを発表しています。このような義務化によって、スタッフの研修プログラムや臨床判断支援ツールに支えられた、最前線の戦略としての薬理学的ディエスカレーションへの移行が加速しています。認知症に関連した攻撃性が蔓延している長期療養施設やメモリーケア施設では、適応外の抗精神病薬の使用を減らし、その代わりにエビデンスに基づいた適切な投与量のレジメンを採用することへの圧力が高まっています。患者の安全性と治療への対応に重点を置く保険償還モデルや病院の業績評価基準は、公的・私的なケア環境全体でこの移行を強化しています。

地域や医療環境における急性期の興奮と攻撃性の治療市場の成長の原動力は？

急性期の興奮と攻撃性の治療市場の成長を牽引しているのは、精神疾患や神経変性疾患の負担増、ケア基準の転換、メンタルヘルスサービスへの世界のアクセス拡大です。北米では、米国が統合失調症、双極性障害、認知症の有病率が高いことに加え、強力な施設能力と迅速な救急医療インフラを有することから、市場をリードしています。FDAによる吸入抗精神病薬や舌下抗精神病薬などの新薬の承認が市場浸透を加速させる一方、病院や長期療養施設では、進化するCMSやJoint Commissionのガイドラインに沿った投薬プロトコルが優先されています。

欧州では、メンタルヘルスに対する意識の高まり、人口の高齢化、精神科医療の非施設化という圧力が、急性期の行動介入能力への投資に拍車をかけています。ドイツ、英国、スカンジナビアの国家医療サービスでは、入院患者と地域社会の両方において、早期かつ低負荷の薬理学的介入を重視する新しい治療モデルが採用されています。アジア太平洋地域では、メンタルヘルスに対する偏見、限られた精神科医療従事者、都市部におけるストレス関連精神疾患の増加により、高いアンメットニーズが発生しています。しかし、中国、インド、オーストラリアでは精神科インフラへの投資が増加しており、対応可能な市場が拡大しています。

セグメント別では、病院の救急部門と精神科入院病棟の利用が最も多いが、外来診療センター、急患診療所、矯正施設、介護施設が高成長セグメントとして浮上しています。個別化精神医療、精密投与、統合ケアモデルの推進が、医薬品イノベーションをさらに促進しています。ヘルスケアシステムが迅速かつ人道的で拡張可能な行動危機管理戦略へと移行する中、世界の急性期の興奮と攻撃性の治療市場は、臨床上の緊急性、規制当局の支援、ドラッグデリバリーの技術的進歩を背景に、持続的な拡大が見込まれています。

セグメント

治療アプローチ（第一世代抗精神病薬、第二世代抗精神病薬、ベンゾジアゼピン系薬剤、α2アドレナリン作動薬、その他の治療アプローチ）、適応症（アルコール離脱症、双極性障害、認知症、うつ病、薬物誘発性興奮・攻撃性、統合失調症、その他の適応症）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の42社）

• AbbVie Inc.
• Alexza Pharmaceuticals Inc.
• Alkermes plc
• Amneal Pharmaceuticals LLC
• Apotex Inc.
• AstraZeneca plc
• Aurobindo Pharma Limited
• Axsome Therapeutics
• Bausch Health Companies Inc.
• Biogen Inc.
• BioXcel Therapeutics
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc（GSK）
• H. Lundbeck A/S
• Hikma Pharmaceuticals PLC
• Impel Pharmaceuticals
• Indivior plc
• Johnson & Johnson

関税影響係数

Global Industry Analystsは、本社国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Acute Agitation and Aggression Treatment Market to Reach US$6.0 Billion by 2030

The global market for Acute Agitation and Aggression Treatment estimated at US$5.1 Billion in the year 2024, is expected to reach US$6.0 Billion by 2030, growing at a CAGR of 2.8% over the analysis period 2024-2030. First-Generation Anti-Psychotics, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Second-Generation Anti-Psychotics segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 5.2% CAGR

The Acute Agitation and Aggression Treatment market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 5.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Acute Agitation and Aggression Treatment Market - Key Trends & Drivers Summarized

Why Is the Clinical Management of Acute Agitation and Aggression Gaining Priority Across Healthcare Systems?

Acute agitation and aggression are critical behavioral emergencies often observed in patients with psychiatric disorders, neurological impairments, substance abuse, or severe metabolic disturbances. These episodes are characterized by sudden, uncontrolled emotional or physical outbursts that can escalate into violence or self-harm, necessitating immediate medical intervention. The increasing prevalence of conditions such as schizophrenia, bipolar disorder, dementia, autism spectrum disorder (ASD), and traumatic brain injury has made the effective treatment of agitation and aggression an urgent focus in emergency rooms, psychiatric units, long-term care facilities, and correctional health environments.

The need for safe, rapid, and patient-centered intervention strategies is further heightened by the potential legal, ethical, and operational risks associated with restraint use and staff injuries. As awareness around mental health and behavioral emergencies grows globally, healthcare providers are under pressure to reduce reliance on physical restraint and seclusion by adopting pharmacologic treatments that offer swift symptom control with minimal sedation or cognitive impairment. This shift is driving demand for fast-acting intramuscular (IM), intravenous (IV), sublingual, and inhalable drug formulations that allow de-escalation without compromising patient dignity or safety.

How Are Advancements in Drug Formulations and Administration Methods Enhancing Therapeutic Impact?

Pharmaceutical innovation is playing a transformative role in the treatment of acute agitation and aggression. A key trend is the development of rapid-onset antipsychotics and benzodiazepines with targeted delivery systems that reduce onset time, improve patient compliance, and minimize the need for invasive restraint. Second-generation antipsychotics (SGAs) such as olanzapine, aripiprazole, and ziprasidone-administered via IM injection-are gaining favor due to their favorable efficacy-to-safety ratio and lower incidence of extrapyramidal side effects compared to first-generation agents like haloperidol.

Emerging delivery systems, including inhaled loxapine and sublingual dexmedetomidine, are further expanding treatment options by offering non-invasive, patient-preferred alternatives that act within minutes. These routes improve medication acceptance in uncooperative patients and reduce the logistical burden on clinical staff. Moreover, novel formulations with dual mechanisms-combining antipsychotic and anxiolytic effects-are showing promise in tailoring treatment to specific patient populations. Clinical trials are also underway exploring agents with receptor selectivity to minimize sedation and cognitive blunting, particularly important in elderly patients with dementia or those in acute care settings.

What Healthcare Trends, Clinical Challenges, and Policy Initiatives Are Fueling Market Growth?

The rising incidence of psychiatric emergencies and comorbid behavioral disorders is prompting hospitals and psychiatric facilities to update their treatment protocols and stock emergency-ready pharmacological solutions. Emergency departments are now treating a broader patient mix-including those with acute substance withdrawal, neurodegenerative disease, intellectual disabilities, and trauma-induced agitation-driving demand for flexible and fast-acting drug regimens. Additionally, with the global shortage of psychiatric beds and rising hospital crowding, rapid pharmacological control of aggression has become essential for improving patient throughput, safety, and care quality.

On the policy front, healthcare accreditation bodies and mental health oversight agencies are issuing stricter guidelines discouraging excessive sedation and physical restraint. These mandates are accelerating the transition to pharmacologic de-escalation as a frontline strategy, supported by staff training programs and clinical decision support tools. In long-term care and memory care facilities, where dementia-related aggression is prevalent, there is increasing pressure to reduce off-label antipsychotic use and instead adopt evidence-based, appropriately dosed regimens. Insurance reimbursement models and hospital performance metrics that emphasize patient safety and treatment responsiveness are reinforcing this transition across public and private care settings.

What Is Driving the Growth of the Acute Agitation and Aggression Treatment Market Across Geographies and Care Settings?

The growth in the acute agitation and aggression treatment market is driven by the increasing burden of psychiatric and neurodegenerative disorders, shifting care standards, and expanding access to mental health services globally. In North America, the U.S. leads the market due to its high prevalence of schizophrenia, bipolar disorder, and dementia, alongside strong institutional capacity and rapid emergency care infrastructure. FDA approvals of new agents such as inhaled and sublingual antipsychotics are accelerating market penetration, while hospitals and long-term care facilities prioritize medication protocols that align with evolving CMS and Joint Commission guidelines.

In Europe, rising mental health awareness, aging populations, and pressure to deinstitutionalize psychiatric care are spurring investment in acute behavioral intervention capabilities. National health services across Germany, the UK, and Scandinavia are adopting new treatment models that emphasize early, low-impact pharmacological intervention in both inpatient and community settings. Asia-Pacific is experiencing high unmet need due to mental health stigma, limited psychiatric workforce, and rising rates of urban stress-related psychiatric episodes. However, growing investment in psychiatric infrastructure in China, India, and Australia is expanding the addressable market.

Segment-wise, hospital emergency departments and psychiatric inpatient units account for the highest usage, but ambulatory care centers, urgent care clinics, correctional facilities, and nursing homes are emerging as high-growth segments. The push for personalized psychiatry, precision dosing, and integrated care models is further driving pharmaceutical innovation. As healthcare systems transition toward rapid, humane, and scalable behavioral crisis management strategies, the global acute agitation and aggression treatment market is poised for sustained expansion-anchored in clinical urgency, regulatory support, and technological advancement in drug delivery.

SCOPE OF STUDY:

The report analyzes the Acute Agitation and Aggression Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Approach (First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist, Other Treatment Approaches); Indication (Alcohol Withdrawal, Bipolar Disorder, Dementia, Depression, Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• AbbVie Inc.
• Alexza Pharmaceuticals Inc.
• Alkermes plc
• Amneal Pharmaceuticals LLC
• Apotex Inc.
• AstraZeneca plc
• Aurobindo Pharma Limited
• Axsome Therapeutics
• Bausch Health Companies Inc.
• Biogen Inc.
• BioXcel Therapeutics
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc (GSK)
• H. Lundbeck A/S
• Hikma Pharmaceuticals PLC
• Impel Pharmaceuticals
• Indivior plc
• Johnson & Johnson

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Acute Agitation and Aggression Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Psychiatric and Neurological Disorders Drives Treatment Demand
  • Increased Emergency Room Visits Linked to Behavioral Agitation Spur Pharmaceutical Innovation
  • Development of Rapid-Acting Therapies Enhances Onset of Action in Acute Settings
  • Shift Toward Non-Invasive and Inhalable Drug Delivery Systems Gains Regulatory Support
  • Expansion of Behavioral Health Services in Hospitals Boosts Institutional Prescribing
  • Clinical Trials Focused on Atypical Antipsychotics Support Broader Indication Approvals
  • Growth in Inpatient and Geriatric Psychiatry Settings Expands Market for Targeted Interventions
  • Demand for Personalized Medicine Fuels Interest in Pharmacogenetic Screening for Response Prediction
  • Innovation in Intranasal and Sublingual Formulations Promotes Ease of Administration
  • Regulatory Push for Patient Safety and De-Escalation Protocols Encourages Therapeutic Alternatives
  • Emphasis on Minimizing Sedation and Preserving Cognitive Function Drives Drug Differentiation
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Acute Agitation and Aggression Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Acute Agitation and Aggression Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Acute Agitation and Aggression Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for First-Generation Anti-Psychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for First-Generation Anti-Psychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for First-Generation Anti-Psychotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Second-Generation Anti-Psychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Second-Generation Anti-Psychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Second-Generation Anti-Psychotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Benzodiazepines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Benzodiazepines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Benzodiazepines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Alpha-2 Adrenergic Agonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Alpha-2 Adrenergic Agonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Alpha-2 Adrenergic Agonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatment Approaches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Treatment Approaches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Treatment Approaches by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Drug-Induced Agitation & Aggression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Drug-Induced Agitation & Aggression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Drug-Induced Agitation & Aggression by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Schizophrenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Schizophrenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Schizophrenia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Alcohol Withdrawal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Alcohol Withdrawal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Alcohol Withdrawal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Bipolar Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Bipolar Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Bipolar Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Dementia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Depression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Depression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Depression by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Acute Agitation and Aggression Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 50: USA Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• JAPAN
  • Acute Agitation and Aggression Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CHINA
  • Acute Agitation and Aggression Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 77: China Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• EUROPE
  • Acute Agitation and Aggression Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Acute Agitation and Aggression Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Acute Agitation and Aggression Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• FRANCE
  • Acute Agitation and Aggression Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 98: France Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• GERMANY
  • Acute Agitation and Aggression Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Germany 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Germany 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Italy 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Italy 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 122: Italy Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Italy Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Italy 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Acute Agitation and Aggression Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 125: UK Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: UK 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 128: UK Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: UK 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 131: UK Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: UK Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: UK 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Spain 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 137: Spain Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Spain Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Spain 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 140: Spain Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Spain Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Spain 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Russia 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 146: Russia Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Russia Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Russia 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 149: Russia Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Russia Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Russia 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Rest of Europe Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Rest of Europe 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Rest of Europe Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Rest of Europe 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Acute Agitation and Aggression Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Acute Agitation and Aggression Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Acute Agitation and Aggression Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Asia-Pacific Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Asia-Pacific 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Acute Agitation and Aggression Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Australia 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 176: Australia Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Australia Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Australia 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 179: Australia Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Australia Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Australia 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• INDIA
  • Acute Agitation and Aggression Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 182: India Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: India 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 185: India Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: India Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: India 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 188: India Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: India Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: India 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: South Korea 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 194: South Korea Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: South Korea Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: South Korea 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 197: South Korea Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: South Korea Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: South Korea 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Asia-Pacific Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Asia-Pacific Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Asia-Pacific 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Acute Agitation and Aggression Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Acute Agitation and Aggression Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Acute Agitation and Aggression Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Latin America 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 218: Latin America Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Latin America Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Latin America 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Argentina 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 224: Argentina Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Argentina Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Argentina 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 227: Argentina Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Argentina Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Argentina 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Brazil 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 233: Brazil Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Brazil Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Brazil 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 236: Brazil Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Brazil Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Brazil 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Mexico 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 242: Mexico Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Mexico Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Mexico 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 245: Mexico Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Mexico Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Mexico 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Latin America Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Latin America 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Latin America Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Latin America 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Acute Agitation and Aggression Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Acute Agitation and Aggression Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Acute Agitation and Aggression Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Middle East 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 266: Middle East Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Middle East Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Middle East 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Iran 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 272: Iran Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Iran Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Iran 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 275: Iran Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Iran Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Iran 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Israel 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 281: Israel Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Israel Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Israel 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 284: Israel Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Israel Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Israel 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Saudi Arabia Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Saudi Arabia 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Saudi Arabia Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Saudi Arabia 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: UAE 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 299: UAE Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: UAE Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: UAE 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 302: UAE Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: UAE Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: UAE 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Middle East Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Middle East 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Middle East Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Middle East 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AFRICA
  • Acute Agitation and Aggression Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Acute Agitation and Aggression Treatment by Treatment Approach - First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Africa 15-Year Perspective for Acute Agitation and Aggression Treatment by Treatment Approach - Percentage Breakdown of Value Sales for First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, Alpha-2 Adrenergic Agonist and Other Treatment Approaches for the Years 2015, 2025 & 2030
  • TABLE 317: Africa Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Africa Historic Review for Acute Agitation and Aggression Treatment by Indication - Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Africa 15-Year Perspective for Acute Agitation and Aggression Treatment by Indication - Percentage Breakdown of Value Sales for Drug-Induced Agitation & Aggression, Schizophrenia, Other Indications, Alcohol Withdrawal, Bipolar Disorder, Dementia and Depression for the Years 2015, 2025 & 2030
  • TABLE 320: Africa Recent Past, Current & Future Analysis for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Africa Historic Review for Acute Agitation and Aggression Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Africa 15-Year Perspective for Acute Agitation and Aggression Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION